Revenue - For the three months ended September 30, 2021, revenue was approximately $29,000, an increase of $1,000 compared to approximately $28,000 for the same period in 2020[159]. - For the nine months ended September 30, 2021, revenue was approximately $0.3 million, a decrease of $0.7 million compared to approximately $1.0 million for the same period in 2020[167]. Research and Development Expenses - Research and development expenses for the three months ended September 30, 2021, were approximately $9.4 million, an increase of $6.9 million from $2.5 million for the same period in 2020[161]. - Research and development expenses for the nine months ended September 30, 2021, were approximately $20.8 million, an increase of $12.6 million from $8.2 million for the same period in 2020[168]. - The company anticipates research and development expenses to increase for the remainder of 2021[162]. General and Administrative Expenses - General and administrative expenses for the three months ended September 30, 2021, were approximately $1.9 million, a decrease of $0.5 million from $2.4 million for the same period in 2020[164]. - General and administrative expenses for the nine months ended September 30, 2021, were approximately $6.4 million, an increase of $0.6 million from $5.8 million for the same period in 2020[169]. Operating Losses and Deficit - As of September 30, 2021, the accumulated deficit was $170.1 million, with expectations of continued significant operating losses[170]. Cash Flow - Net cash used in operating activities was approximately $16.8 million for the nine months ended September 30, 2021, compared to approximately $11.6 million for the same period in 2020[173]. - Net cash provided by financing activities was $36.3 million for the nine months ended September 30, 2021, compared to $27.6 million for the same period in 2020[176].

Therapeutics NASDAQ: CKPT Corporate Presentation September 2021 Checkpoint Therapeutics Safe Harbor Statement This presentation may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For such forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Such statements incl ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |----------------------------------------------------------------|-------------------------------------------------------------------------------- ...

NASDAQ: CKPT CORPORATE PRESENTATION June 2021 Safe Harbor Statement This presentation may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For such forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, any statement ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-38128 CHECKPOINT THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ...

NASDAQ: CKPT CORPORATE PRESENTATION March 2021 Safe Harbor Statement This presentation may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For such forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, any statemen ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per CKPT NASDAQ Capital Market | --- | --- | --- | --- | |-----------------------------|-------|-------|-------| | | | | | | Large accelerated filer | ☐ | | | | Non-accelerated filer | | | | | | ☒ | | | | Emerging growth company | ☒ | | | Acceleratedfiler Smallerreportingcompany ☐ UNITED STATES SECURITIES AND EXCHANGE CO ...

NASDAQ: CKPT CORPORATE PRESENTATION January 2021 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates", expects", plans", believes", "intends", and similar words or phrases. Such statements involve risks and uncertainties that could cause Checkpoint Therapeutics' actual results to differ materially from th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-38128 CHECKPOINT THERAPEUTICS, INC. (Exact name of registrant as specified in its char ...

NASDAQ: CKPT CORPORATE PRESENTATION August 2020 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates", expects", plans", believes", "intends", and similar words or phrases. Such statements involve risks and uncertainties that could cause Checkpoint Therapeutics' actual results to differ materially from the ...